Alpa Laboratories' Q1 FY 2025-26 Quarterly Results

Result Summary

• Alpa Laboratories Ltd reported a 12.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.8%.
• Its expenses for the quarter were down by 7.7% QoQ and 10.3% YoY.
• The net profit increased 231.5% QoQ and increased 130.8% YoY.
• The earnings per share (EPS) of Alpa Laboratories Ltd stood at 5.6 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alpa Laboratories Ltd is a company operating within the pharmaceutical industry. It focuses on manufacturing and marketing pharmaceutical products. The company's portfolio may include a range of pharmaceutical formulations, which could be in the form of tablets, capsules, and injectables. While specific recent developments about Alpa Laboratories Ltd are not available in the provided data, companies in this sector typically engage in activities such as research and development, expanding product lines, or entering new markets to drive growth. Alpa Laboratories Ltd might be involved in similar activities to leverage its position in the pharmaceutical industry.

Revenue

In Q1FY26, Alpa Laboratories Ltd reported a total income of ₹31.06 crores. This marks an increase of 12.7% from the previous quarter (Q4FY25), where the total income was ₹27.57 crores. When compared to the same quarter in the previous year (Q1FY25), total income rose by 16.8% from ₹26.60 crores. These figures indicate a growth trajectory in revenue generation over both the quarterly and yearly perspectives. The company appears to have achieved a notable increase in its income, which could be attributed to various strategic or operational factors within the company.

Profitability

Alpa Laboratories Ltd's profitability metrics for Q1FY26 show significant improvements. The profit before tax (PBT) for the quarter was ₹11.77 crores, reflecting a substantial increase of 76.5% from the previous quarter's PBT of ₹6.67 crores. Compared to Q1FY25, where the PBT was ₹5.10 crores, there is an increase of 130.8%. The profit after tax (PAT) for Q1FY26 matched the PBT at ₹11.77 crores, indicating no tax expenses during this period. The PAT increased by 231.5% from the previous quarter's ₹3.55 crores and by 130.8% from the ₹5.10 crores reported in Q1FY25. The absence of tax expenses in the current quarter likely contributed to the boost in net profits.

Operating Metrics

The financial data highlights some key operating metrics for Alpa Laboratories Ltd. Total expenses in Q1FY26 amounted to ₹19.29 crores, which is a decrease of 7.7% from the previous quarter's total expenses of ₹20.91 crores. Year-over-year, this represents a 10.3% reduction from ₹21.50 crores in Q1FY25. The earnings per share (EPS) for Q1FY26 was reported at ₹5.60, which signifies a dramatic increase of 229.4% from the previous quarter's EPS of ₹1.70 and a rise of 133.3% from the ₹2.40 recorded in Q1FY25. These metrics reflect significant improvements in operational efficiency and shareholder value.